Clinical trial · Observational
Neurocognition After Gamma Knife Radiosurgery for Multiple Brian Metastases
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): Poor accrual. Investigator decision.
Summary
Brief summary (as posted)
Cancer which spreads to the brain (brain metastases) is a common and significant problem. Historically, whole-brain radiotherapy has been used to treat these patients but has a negative effect on cognition. Radiosurgery is an alternative treatment with potential for fewer cognitive side effects. The impact of radiosurgery alone on the cognitive function of patients with multiple brain metastases is not well studied. We propose a pilot study at the Winnipeg Centre for Gamma Knife Surgery to examine this issue.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasm Metastases | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gamma knife radiosurgery | Radiation | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- Brain metastases (>= 4)
- description
- Patients with pathologically proven solid tumour malignancy who have \>=4 brain metastases will be treated with gamma knife radiosurgery.
- interventionNames
- Radiation: Gamma knife radiosurgery
Primary outcomes (1)
- measure
- Hopkins Verbal Learning Test - Revised (HVLT-R)
- timeFrame
- 4 months after radiosurgery
Secondary outcomes (3)
- measure
- Neurocognitive battery
- timeFrame
- 4 months after radiosurgery
- description
- Other neurocognitive tests will include Trail making test A and B (TMT), Controlled Oral Word Association (COWAT), Test of Premorbid Functioning, Ruff Figural Fluency Test, Animal Naming, Brief Visuospatial Memory Test - Revised, WMS-III Digit Span, WMS-III Spatial Span, and the Symbol Digit Modalities Test.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Pathologically proven solid tumour malignancy * Age \>= 18 years * Karnofsky performance status \>= 70 * \>= 4 brain metastases, all eligible to be treated with radiosurgery * All brain metastases \<= 4.0 cm in any diameter * Pre-treatment contrast enhanced MRI brain \<= 42 days prior to enrollment * Patient able to provide his/her own written informed consent Exclusion Criteria: * Prior radiosurgery, whole brain radiotherapy, or cranial radiotherapy * Previous surgical resection of brain metastasis (biopsy is allowed) * Prior chemotherapy ≤ 7 days prior to enrollment * Planned chemotherapy during radiosurgery * Leukemia, lymphoma, germ-cell tumour, small-cell lung cancer diagnosis * Brainstem metastasis * Leptomeningeal metastases * Contraindication to MR imaging with contrast * Pregnant or nursing women
References
Publications (0)
Data not yet available